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Aaron Gerds,1 Mary Fox-Geiman,2 Kevin Dawravoo,1 Tulio Rodriguez,1 Amir Toor,1,4
Scott Smith,1 Karen Kiley,3 Donna Fletcher-Gonzalez,2 Chindo Hicks,4 Patrick Stiff1Nonrandomized trials suggest that pegfilgrastim, a pegylated granulocyte colony-stimulating factor, could be
used in lieu of filgrastim after autologus peripheral blood stem cell transplantation. This phase III, random-
ized, double-blinded, placebo-controlled trial compared the efficacy, costs, and safety of single-dose pegfil-
grastim (single 6 mg dose) versus daily filgrastim (5 mg/kg/day) for this indication. Seventy-eight patients,
matched for age, sex, underlying disease, stage, and CD34/kg transplant dose were enrolled. Cytokines
were started on day 11 posttransplant and continued to an absolute neutrophil count (ANC) of 5 109/L
for 3 days or 10 109/L for 1 day. The median time to neutrophil engraftment (ANC.1.5 109/L for 3 days
or 5 109/L for 1 day) was the same in both groups (12 days). No differences in platelet engraftment
(11 versus 13 days), number of platelet transfusions (5 versus 4), percent with positive cultures for bacterial
pathogens (23% versus 15%), days of fever (1 versus 2), deaths prior to engraftment (1 versus 1), or duration
of hospital stay (19 versus 19 days) were seen between the pegfilgrastim and filgrastim groups, respectively.
Using the average wholesale price for doses used in this trial, there was a per-patient savings of $961 for the
pegfilgrastim group (P\.001). This phase III study failed to demonstrate a difference in time to neutrophil
engraftment or any clinical sequelae between pegfilgrastim and filgrastim when given post-APBSCT, with
pegfilgrastim achieving a cost savings over filgrastim.
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High-dose chemotherapy/radiotherapy followed
by autologus peripheral blood stem cell transplantation
(APBSCT) is a potentially curative therapy for a num-
ber of chemosensitive malignancies. As high-dose
therapy regimens produce severe pancytopenia for 7-
14 days posttransplant, febrile neutropenia and infec-
tion can develop, which are associatedwith a significant
risk of morbidity and mortality [1-3]. Recombinant
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have been shown to accelerate engraftment following
APBSCT, decrease the number of bacterial infections,
number of days on antibiotics, and shorten the length
of hospital stay [4-9]. Three studies have additionally
shown nonsignificant trends toward lower overall costs
in patients receiving these cytokines [6,7,10].
Filgrastim (r-met Hu-G-CSF), a human G-CSF
produced by recombinant DNA technology is 1 such
FDA agent approved for this indication [11]. Cova-
lently bonding a 20-kD polyethylene glycol (PEG)
molecule to filgrastim decreases its plasma clearance,
which leads to an increased half-life of 33.2 hours com-
pared to the 3.5 hours for G-CSF [12]. Despite the dif-
ference in half-life, this compound, pegfilgrastim,
possesses similar clinical activity when used to prevent
infections in the neutropenic patient [13,14]. Although
small nonrandomized trials have suggested that pegfil-
grastim could be used in lieu of filgrastim to speed
hematopoietic reconstitution after APBSCT, the data
are inconsistent as to whether this agent shortens the
period of neutropenia posttransplant compared to
G-CSF, and no large phase III trial data exist
[15-19]. This phase III, randomized, double-blinded,
Biol Blood Marrow Transplant 16:678-685, 2010 679PegG versus G in Autologous Transplantationplacebo-controlled comparative trial of pegfilgrastim
versus filgrastim after APBSCT was therefore under-
taken to compare the efficacy, costs, and safety of the
2 treatments in patients receiving myeloablative pre-
parative regimens.PATIENTS AND METHODS
Patients
Adults undergoing an APBSCT for multiple mye-
loma (MM), lymphoma, testicular, or ovarian carci-
noma were candidates for this phase III, prospective,
randomized, double-blinded, placebo-controlled com-
parative trial of pegfilgrastim versus filgrastim. Patients
were eligible if they were greater than the age of
18 years, had a SWOGperformance status of#2, a cre-
atinine clearance$50 mL/min, as well as a total biliru-
bin level\1.5 mg/dL and aspartate aminotransferase
(AST)\2 times the upper limit of normal. In addition,
a minimum of .2 106 CD341cells/kg needed to be
collected for transplant. All patients provided written
informed consent by completing a form approved by
the institutional review board.
PBSC Collection and Transplantation
PBSC were mobilized for collection using cyto-
kines alone as previously described by daily 12-liter
aphereses starting on day 5 of mobilization [20,21].
The goal was to collect a maximum of 4 106
CD341/kg from a maximum of 5 consecutive daily
apheresis procedures. The stem cells were cryopre-
served in low molecular weight hydroxyethyl starch
and dimethylsulfoxide and held at 280 C [22].
Conditioning regimens included total body irradi-
ation (TBI) (12 Gy in 8 fractions over 4 days) with
etoposide (60 mg/kg) and cyclophosphamide (Cy)
(100 mg/kg; TBI/VP/Cy), TBI1Cy (60 mg/kg;
TBI/Cy), Ifosfamide (10 g/m2, Carboplatin [area un-
der the curve, AUC 28], and Etoposide (2.4 g/m2;
ICE), busulfan (Bu) (16 mg/kg), and Cy (120 mg/kg;
Bu/Cy), paclitaxel (700 mg/m2), mitoxantrone
(90 mg/m2), and carboplatin (AUC 28; TANC), and
BCNU (15 mg/kg), etoposide (60 mg/kg), and Cy
(100 mg/kg; BCV), BCNU (300 mg/m2), and etoposi-
de(0.8 g/m2), Ara-C (1.6 g/m2), melphalan (Mel;
140 mg/m2; BEAM), and Mel (200 mg/m2). On the
day of transplantation (designated as day 0), the
PBSC were rapidly thawed and infused through
a central venous catheter.
Clinical Management
Microbial prophylaxis consisted of acyclovir 5 mg/
kg orally every 12 hours from day 11, fluconazole
200 mg orally every 12 hours starting on day 11, and
prophylactic norfloxacin 400 mg orally twice daily,beginning on the same day as their conditioning
regimen, and continued until complete engraftment
[23-25]. Neutropenic fever was defined as a fever above
38.4C once or above 38.2C on 3 consecutive read-
ings with an absolute neutrophil count (ANC)
\0.5 109/L, and was treated with imipenem/cilasta-
tin 500 mg intravenously every 8 hours [26]. Packed
red blood cell and platelet transfusions were given
when hemoglobin or platelet levels were below 8 g/
dL or 15 109/L, respectively. All blood products
were irradiated and filtered prior to infusion [27].
Protocol Therapy
Patients were randomized on day 0 in a 1:1 ratio to
receive either a single 6 mg subcutaneous injection of
pegfilgrastim along with daily filgrastim placebo, or
daily subcutaneousfilgrastim injections at 5 mg/kg daily
plus a singe injection of pegfilgrastim placebo on day
11, starting approximately 24 hours after the comple-
tion of the PBSC infusion. Filgrastim or pegfilgrastim
placebo was continued until sustained engraftment, as
defined in prior Phase III trials as ANC 5 109/L for
3 days, or 10 109/L for 1 day, or through day 125
posttransplant. Patients not achieving an ANC of
.0.5 109/L by day119 after transplant were permit-
ted to receive opened-label filgrastim.
Statistical Methods
The primary endpoint for this study was a compar-
ison to the time to a neutrophil engraftment of
$1.5 109/L 3 days or 5 109/L 1 day. Second-
ary endpoints included time to resolution of severe
neutropenia (of$0.5 109/L 3 days), length of hos-
pital stay, incidence of infections, time to a platelet en-
graftment as measured by count recovery to
.20 109/L for 7 days, the number of platelet and
packed red blood cell (PRBC) transfusions, the average
number of filgrastim doses in the filgrastim arm, num-
ber of doses of rescue filgrastim, costs, and overall
survival (OS).
A sample size of 78, 39 per treatment group, was
required to provide a statistical power of 95% to detect
a clinically significant difference between the 2 groups
of 2 days in engraftment, assuming a standard devia-
tion of 2.4 days and a 1-sided a of .05. To control
for differences in speed of engraftment resulting
from differing CD341/kg stem cell doses, patients
were stratified based on the CD341/kg cell dose re-
ceived (\5.0 106/kg versus $0.5 106/kg). Patients
were also stratified by preparative regimen (TBI con-
taining or non-TBI containing) to account for differ-
ences in mucotoxic potential. Within a stratum,
enrolled patients were randomized in a 1:1 fashion
into the 2 study groups. The filgrastim and pegfilgras-
tim groups were compared using the Student’s t-test
for continuous variables, and categoric variables were
680 Biol Blood Marrow Transplant 16:678-685, 2010A. Gerds et al.examined with the chi-square test. A linear regression
model was used to examine confounders on time to en-
graftment. A 2-sided p value of\.05 was considered to
be significant. Survival analyses were plotted as Ka-
plan-Meier curves and comparedusing the log-rank test.RESULTS
Patient Characteristics
In all, 78 patients were enrolled in this study at our
institution between November of 2003 and May of
2007 (Figure 1). Patients were consecutively enrolled,
if eligible for this trial, and there was no requirement
for specified posttransplant cytokine administration
mandated by the disease therapy trial the patient was
also enrolled on. Thirty-nine patients each were ran-
domized to the pegfilgrastim and filgrastim groups.
The clinical characteristics are shown in Table 1.
The mean CD341 stem cell doses infused were 4.1
and 4.7 106/kg (P5 .68) for the pegfilgrastim and
filgrastim groups, respectively. The groups were
matched for age, sex, weight, and underlying disease.Assessed for eligibi
Patients randomly ass
Lost to follow-up (n = 0 )
Discontinued intervention (n = 1)
-Early Deaths (n = 1)
Allocated to intervention (n = 39)
Received allocated intervention (n = 39 )
Did not receive allocated intervention (n = 0)  
Analyzed (n = 39)
Excluded from analysis (n =  0)
Figure 1. Patient enrollment and mAll patients received protocol therapy and were evalu-
able for the endpoints.
Engraftment Data
The median time to an ANC of 1.5 109/L for 3
days or 5.0 109/L for 1 day was 12 days in both
groups (Table 2 and Figure 2). The median time to
resolution of severe neutropenia (ANC $0.5 109/
L 3 days) was 9 and 10 days, respectively, for the
pegfilgrastim and filgrastim groups (P5 .15). When
adjusted for stem cell dose and conditioning regimens
with TBI there was no significant difference in time to
engraftment (P5 .11). In addition to the primary end-
point, we examined several other measures of hemato-
poietic recovery. Patients in either arm received a
mean of 12 injections, either filgrastim placebo or fil-
grastim, to reach the primary endpoint engraftment
level. However, the protocol defined cytokine discon-
tinuation engraftment endpoint of an ANC of 5.0 
109/L for 3 days or 10  109/L for 1 day was reached
in only 44% of the patients in the pegfilgrastim group
compared to 95% in the filgrastim group. The median
number of doses to reach this endpoint was 25 for thelity (N = 109 )
Excluded (n = 31 )
Not meeting inclusion criteria (n = 17)
Refused to participate (n = 8 )
Other reasons (n = 6-protocol 
mandated therapy)
igned (n = 78 )
Lost to follow-up (n = 0)
Discontinued intervention (n = 1)
-Early Deaths ( n = 1)
Analyzed (n = 39)
Excluded from analysis (n =  0)
Allocated to intervention (n = 39)
Received allocated intervention (n = 39)
Did not receive allocated intervention (n = 0) 
ovement through the study.
Table 1. Patient Characteristics
Filgrastim Pegfilgrastim p value
Number of patients 39 39
Age (median, range) 56 (20-80) 56 (22-79) 0.7374
Sex
Male (%) 12 (31) 12 (31) 1.00
Female (%) 27 (69) 27 (69) 1.00
Weight (mean, kg) 75.799 82.211 0.053
Disease
Hodgkin lymphoma 7 (18%) 6 (15%)
Non-Hodgkin lymphoma 14 (36%) 21 (54%)
Multiple myeloma 15 (38%) 8 (21%)
Solid tumor (testicular, ovarian) 3 (8%) 4 (10%)
Remission Status
Complete remission 1 10 (26%) 9 (23%)
Greater than complete remission 1 11 (28%) 10 (26%)
Partial remission 1 or greater 12 (31%) 15 (38%)
Disease progression or relapse 5 (13%) 5 (13%)
Nummber of prior regimens (median, range) 2 (1-5) 2 (1-5) 0.67
Time to transplant in months (median, range) 20 (4-168) 15.5 (4-242) 0.91
Prior radiation to marrow 2 (5%) 4 (10%)
Conditioning Regimen
TBI/VP/Cy or TBI/Cy 13 (33%) 12 (31%)
ICE 2 (5%) 1 (3%)
Bu/Cy 14 (36%) 5 (13%)
TANC 1 (3%) 3 (8%)
BCV 7 (18%) 10 (26%)
BEAM 0 (0%) 4 (10%)
Melphalan 2 (5%) 4 (10%)
TBI containing 13 (33%) 12 (31%)
Non-TBI containing 26 (67%) 27 (69%)
Graft data
Mobilization
G-CSF 32 (82%) 29 (74%)
GM-CSF and GCSF 7 (18%) 6 (15%)
AMD 3100 0 (0%) 4 (10%)
CD34+ cells x 106/kg infused (median, range) 4.13 (1.82-12.11) 4.21 (1.78-18.99) 0.75
TBI indicates total body irradiation; VP, etoposide; Cy, cyclophosphamide; Bu, busulfan; G-CSF, granulocyte colony-stimulating factor; GMCSF, granu-
locyte macrophage colony-stimulating factor.
Biol Blood Marrow Transplant 16:678-685, 2010 681PegG versus G in Autologous Transplantationpegfilgrastim group and 13 for the filgrastim group
(P\ .0001). No patient required opened-label, rescue
filgrastim to achieve engraftment.
When examining the mean ANC over the first 25
days after transplant, there is a sharp increase in the
ANC on day 12 in both groups followed by a decline
starting on day15. The ANC of both groups followed
a similar recovery pattern except for days 112 to day
116, when the median ANC for the filgrastim group
was significantly higher than that of pegfilgrastim.
There was no significant difference in the platelet
engraftment between the pegfilgrastim and filgrastim
study arms (11 versus 13 days, P5 .29). Each arm
also received the similar amount of platelet (5 versus
4, P5 .30) and RBC transfusions (2 versus 2,
P5 .052) (Table 3). The mean platelet counts for
each group declined from day 0 to day 17, thenTable 2. Hematologic Recovery
Filgrastim
Days to ANC 0.5xl09/L (median, range) 10 (8-15)
Days to ANC 1.5 x l09/L (median, range) 12 (9-16)
Days to ANC 5 x l09/L (median, range) 13 (9-22)
Days to platelets 20 x l09/L (median, range) 10 (8-68)
ANC indicates absolute neutrophil count.steadily increased to pretransplant levels until engraft-
ment. There was no significant difference in the mean
platelet counts for either group in the first 25 days after
transplant (Figure 3).Toxicities
There were no grade III or IV toxicities, includ-
ing bone pain, which could be specifically attributed
to either of the study drugs. Two patients (one
from each arm) died while on the study. Both patients
died from infection-related sepsis prior to neutrophil
engraftment (on day 17 and day 113). The median
number of days with febrile neutropenia of the peg-
filgrstim arm was 1 (range: 0-7 days), and 2 for the fil-
grastim arm (range: 0-12 days). There was no
significant difference in the incidence of positivePegfilgrastim p value
9 (8-13) 0.15
12 (9-24) 0.21
25 (10-18) 0.001
11 (7-21) 0.29
Figure 2. Neutrophil engraftment after transplant. Kaplain-Meier plot
of time to an ANC of 1.5 109/L for 3 days, or 5 109/L for 1 day in the
filgrastim group compared to the pegfilgrastim group.
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as well (23% in pegfilgrastim versus 15% in filgras-
tim, P5 .39).
The median hospital duration was the same for
each of the groups (19 days). The median follow-up
of survivors was 14 months. At the time of analysis,
there was no significant difference in survival at day
1100 (P5 .67) or at 1 year (P5 .97) (Figure 4).Cost Analysis
In the pegfilgrastim arm, patients received a single,
fixed dose of 6 mg on day11 after APBSCT. In the fil-
grastim arm, the study drug was given daily at 5 mg/kg
daily for amedian number of 12 days (range: 9-16 days)
starting on day11 after APBSCT to reach an ANC of
1.5 109/L for 3 or 5.0 109/L x1 day. Considering
the average wholesale price in U.S. dollars for the ac-
tual doses used in this trial, the cost per patient was
a mean of $3547.40 USD with pegfilgrastim and
$4508.20 USD with filgrastim. This resulted in
a per-patient savings of $960.80 USD for the pegfil-
grastim group compared to the filgrastim group using
this engraftment endpoint (P\ .001).DISCUSSION
We present data from the first randomized double
blinded trial of pegfilgrastim versus filgrastim follow-
ing APBSCT. In this study, we demonstrated thatTable 3. Transfusions, Infectious Complications, and Toxicity
Filgra
Number of platelet transfusions (median, range) 4 (0-
Number of RBC transfusion (median, range) 1 (0-
Duration of hospital stay (median, range) 19 (12
Days of febrile neutropenia (median, range) 2 (0-
Nummber of documented infections 6
Days with grade III or VI mucocitis (median, range) 0 (0the outcomes in both groups were similar in terms of
times to ANC engraftment and all potential sequelae
of prolonged neutropenia. Other endpoints examined
also yielded similar results in the 2 groups examined,
in particular, with respect to transfusions and hospital
stay as well as posttransplant mortality. We demon-
strated that because pegfilgrastim is cleared by neutro-
phil absorption [13,28], our patients were able to
achieve ANC engraftment despite their receiving
only a single dose posttransplant rather than repeated
daily doses of filgrastim.
Pegfilgrastim has been used before in the postauto-
transplant setting but the results have been conflicting.
Farese et al. [29] first studied pegfilgrastim after autol-
ogous transplant in rhesus macaques, and showed that
a single dose was as effective as daily filgrastim in
neutrophil recovery. Subsequently, Musto et al. [30]
looked at an 11-patient cohort with MM, non-
Hodgkin lymphoma, and acute myelogenous leukemia
conditioned withMel, BEAM, or TBI/Cy. Patients re-
ceived pegfilgrastim on day 13 post-ABPSCT and
were compared retrospectively to matched historical
controls who received standard doses of filgrastim
starting on day 15 posttransplant. The median time
to neutrophil engraftment in the pegfilgrastim group
was 2 days shorter compared to the filgrastim group
(10 versus 12). There was also a suggestion of cost ben-
efit in this small study. Jagasia et al. [15] conducted
a larger study in which 38 patients with MM and lym-
phoma, conditioned with Mel or BCV, who received
pegfilgrastim on day 11. Again, these patients were
compared to a historical cohort in which filgrastim
was started on either day 11 or day 14. Engraftment
times were found to be shorter in the pegfilgrastim
group than the filgrastim group (10 versus 13.7 days;
P\ .05). However Martino et al. [16] treated 37 pa-
tients with multiple myeloma, who were also condi-
tioned with melphalan, and given pegfilgrastim on
day 11, and showed no significant difference in
engraftment versus a group of historic controls given
filgrastim on day 15. Likewise Vanstraelen et al. [18]
conducted a study comparing 20 patients with lym-
phoma and MM conditioned with TBI/Cy, BEAM,
or Mel, receiving pegfilgrastim versus historical con-
trols receiving filgrastim, both starting on day 11,
and again found no difference in neutrophil recovery
(9 versus 8 days). More recently, Ballestrero et al.
[19] looked at 44 patients undergoing autologusstim Pegfilgrastim p value
14) 5 (1-15) 0.30
4) 2 (0-5) 0.052
-26) 19 (10-36) 0.32
12) 1 (0-7) 0.13
9 0.16
-14) 1 (0-19) 0.44
Figure 3. Platelet count (109/L) in the first 25 days after transplant.
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to 25 historic controls. These patients were condi-
tioned with thiotepa in combination with Mel or mi-
toxantrone, ICE, or BEAM, and again were found to
have no difference in time to neutrophil recovery (10
versus 9.5 days) when starting both pegfilgrastim and
filgrastim on day 15.
A nonblinded, randomized, controlled study by
Staber et al. [31] showed a significant trend to shorter
engraftment with pegfilgrastim versus filgrastim (8.3
versus 9.5 days). Patients with acute leukemia, MM,
non-Hodgkin and Hodgkin lymphoma were condi-
tioned with TBI/Cy, BEAM, BCVM, or Mel, with
pegfilgrastim given on day 15 and filgrastim was on
day 17. Our study, the first randomized, placebo-
controlled study comparing the 2 agents as well as
the studies conducted by Vanstraelen et al. [18] and
Ballestrero et al. [19], started each growth factor on
the same day, where the other studies listed started
each growth factor on different days. The delay in
starting filgrastim after that of pegfilgrastim may ex-
plain the earlier engraftment times for pegfilgrastimFigure 4. Kaplan-Meier plot of OS in the in the filgrastim and pegfil-
grastim groups.in these studies, and potentially why we did not see
a difference in engraftment times for the 2 arms.
We did, however, see a significant difference in
count recovery to the traditional Phase III trial end-
point for filgrastim cessation, that is, an ANC of
5.0 109/L for 3 days or 10 109/L for 1 day.
Although only 44% of the patients in the pegfilgrastim
group compared to 95% in the filgrastim group
reached this endpoint, there was no subsequent fall
off our neutrophil counts nor any sequelae of this rel-
atively lower ANC period in rates of infection, febrile
neutropenia, treatment-related mortality, or 100-day
survival in the pegfilgrastim group. The significantly
higher ANC from day 112 to day 116 between the
2 arms indeed was most likely due to the receptor-me-
diated clearance of pegfilgrastim as the white count re-
covered, leading to lowered serum cytokine levels.
We also found no differences in other measures of
hematologic recovery, that is, time to platelet engraft-
ment, platelet transfusions, or packed red cell transfu-
sions. These results were similar to those seen in the
various pilot studies [15,17-19]. Because pegfilgrastim,
once given, maintains constant serum levels until
recovery, and may have shunted hematopoietic stem
cells away from the megakaryocytic lineage to the
granulocytic lineage, we investigated the pattern of
platelet count recovery in our patients. Similar to neu-
trophil recovery, we found no difference in the speed
of platelet count recovery. This likely is because of
the ability of pegfilgrastim to upregulate the
expression of primitive transcription factors such as
HOXA9 and GATA3, leading to a robust multilineage
engraftment despite the lower peak ANC engraftment
seen in our patients [32]. Our speculation that recipi-
ents of pegfilgrastimmight also have superior lympho-
cyte and immune reconstitution and that this might
have clinical implications can not be proven consider-
ing the small numbers of a relatively heterogenous
population [33,34].
With apparent equivalency between the 2 groups,
the choice of 1 versus the other therapy then would de-
pend on quality of life and costs. No one would dispute
the improvement in the quality of life afforded by a sin-
gle dose of pegfilgrastim given on day 11 posttrans-
plant versus repeated subcutaneous daily doses of
filgrastim. Although we did not see a difference in
the amount of grade I-II bony pain in the 2 groups,
it is likely that the narcotic use for mucositis and phar-
yngits obscured any potential differences between the
2 arms. Although a single dose of pegfilgrastim costs
substantially more than a single dose of filgrastim,
using the drug discontinuation endpoint that has
been traditionally used in previous clinical trials, we
found a cost benefit in the pegfilgrastim group of
$960.85 USD for the pegfilgrastim arm. However,
multiple studies have demonstrated that delaying the
initiation of filgrastim until day 15 posttransplant
684 Biol Blood Marrow Transplant 16:678-685, 2010A. Gerds et al.does not significantly delay neutrophil recovery and
engraftment [35,36]. If one assumes that this would
have occurred in our study, then delaying the filgras-
tim until day 15, patients on this arm would have
received only 7 doses of drug to full engraftment
thereby leading to an average cost savings for the
filgrastim arm of $1212.56 USD per patient over the
cost of the pegfilgrastim arm. However, considering
the delayed onset studies of Jagasia et al., Musto
et al., and Staber et al. [15,30,31], it would need to
be proven that this altered strategy led not only to sim-
ilar engraftment times but also no difference in down-
stream events as well. Nevertheless, given the overall
costs of transplantation this additional cost may be
appropriate to consider in those who have previously
experienced severe discomfort from repeated daily
doses of filgrastim.ACKNOWLEDGMENTS
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